Read our Recent Headlines


Sep 24, 2018 by Dave Sobek

September 24 Biotech Update

An interesting start to the week, although we still like real M&A or business development. Unlike previous weeks, however, there is actually some interesting news to discuss. The sector is.

Share 0 Comments Read more
Sep 24, 2018 by Jason DeLorenzo

Dave Trading – September 2018

*** David Sobek is a disciplined value investor.  Using models, research, and fundamental data, David devises a value for biotech stocks, buys when significantly undervalued, and sells when significantly overvalued.***.

Sep 20, 2018 by Dave Sobek

September 20th Biotech Update

Still a boring market in terms of news. The sector appears to have successfully defended the bottom end of its range but one could argue it done so simply by.

Sep 18, 2018 by Dave Sobek

September 18 Biotech Update

The sector struggled yesterday and it still looks like testing the bottom on the range is possible. Perhaps the China tariffs news cleared the market a little and we might.

Sep 17, 2018 by Joe Gantoss

XENE Pipeline Keep Growing – Is XEN007 The Next Surprise?

Last week, Xenon pharmaceuticals (XENE) passed one of the most important tests in the stock market, where the share price closed on Friday at $14.05, above the $14.03 resistance line,.

Sep 17, 2018 by Dave Sobek

September 17 Biotech Update

Not a great start to the week in terms of trading as it looks like we are set to retest the bottom on the range (yet again). As long as.

Sep 16, 2018 by Joe Gantoss

SRPT’s CEO Fireside Chat at Morgan Stanley Conference

Sarepta (SRPT) had a great run last week, a kick off following MS fireside chat, closing at $152.76 the highest “close” since June 21st (highest 52W close 06/20 was $153.69).

More From All Reports

Introduction


Overview

Chimera Research Group provides completely independent and actionable investment and trading ideas backed by comprehensive fundamental research and analysis for listed companies in the biotech and pharmaceutical sectors. Our coverage focuses on early stage companies with impending FDA decisions or clinical trial results but also includes mid-to-large cap bio-pharma companies where there exists specific catalysts. Our Trade Ideas are designed to maximize the risk reward profile. Our Research Reports outline the top up-and-coming catalysts that represent the best opportunities for traders and investors.


The biopharmaceutical sector offers significant opportunities to generate big returns yet can be risky and difficult to navigate. Subscribe to Chimera Research Group and proceed with confidence.

Get Started!


      Join      

 Learn More